# A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

> **NCT07264816** · PHASE2 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** BL-M07D1
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07264816
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-03
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264816, "A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07264816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*